Pembrolizumab and Doxorubicin Hydrochloride in Treating Patients With Sarcoma That is Metastatic or Cannot Be Removed by Surgery
NCT02888665 is a phase 1/2 interventional trial sponsored by Fred Hutchinson Cancer Center. As of 21 Nov 2026, it is completed. It studies Doxorubicin and Pembrolizumab in Sarcoma. The registry lists an enrollment of 37 participants at 1 site in 1 country. The registry lists a start date of 5 Dec 2016 and a primary completion date of 17 Mar 2020. One of its registered investigators has a FindMyKOL profile.
Key facts
Registry attributes as recorded on the ClinicalTrials.gov study record.
| Field | Value |
|---|---|
| Registry ID | NCT02888665 |
| Status | Completed |
| Phase | Phase 1/2 |
| Study type | Interventional trial |
| Lead sponsor | Fred Hutchinson Cancer Center |
| Enrollment | 37 |
| Registered sites | 1 |
| Countries | 1 |
| Conditions | Sarcoma |
| Drugs | Doxorubicin and Pembrolizumab |
| Start | 5 Dec 2016 |
| Primary completion | 17 Mar 2020 |
| Study completion | 9 Oct 2020 |
| Last update posted | 26 May 2021 |
Registered summary
The lay summary the sponsor registered on ClinicalTrials.gov.
Investigators
The overall officials registered on this study. Names that resolve to a FindMyKOL profile link to it; the rest are shown as registered.
- Seth Pollack
Fred Hutch/University of Washington Cancer Consortium
Principal InvestigatorKOL profile →
A profile link is shown only when the registered name resolves to a person record with a confident, namesake-checked match; ambiguous names stay unlinked.
Sites
1 registered facility, with the per-site recruitment status where the registry publishes one. ClinicalTrials.gov does not publish per-site enrollment counts.
- Fred Hutch/university of Washington Cancer Consortium
Seattle
United States, by state
Site investigator names are published by ClinicalTrials.gov only while a study recruits, so completed studies list sites without them.
Drugs studied
The drug and biological interventions registered on this study, normalized to their RxNorm ingredient where possible.
Questions about NCT02888665
Each answer restates registry values shown on this page.
What is NCT02888665?
NCT02888665 is a phase 1/2 interventional trial sponsored by Fred Hutchinson Cancer Center. It studies Doxorubicin and Pembrolizumab in Sarcoma.
Who leads NCT02888665?
The registry names Seth Pollack (principal investigator, Fred Hutch/University of Washington Cancer Consortium) as the overall official.
Where does NCT02888665 run?
The registry lists 1 site in 1 country. Every site with a stated country is in one country: United States.
Which drugs does NCT02888665 study?
The registered drug and biological interventions are Doxorubicin and Pembrolizumab.
When did NCT02888665 end?
The registry lists a primary completion date of 17 Mar 2020 and a study completion date of 9 Oct 2020. The sponsor last updated the record on 26 May 2021.
Source: ClinicalTrials.gov, via the CTTI AACT database, data as of 21 Nov 2026. Registry facts are shown as registered by the study sponsor; FindMyKOL does not interpret them.